Has first-line therapy had an impact on general outcome in metastatic breast cancer? Journal Article
| Authors: | Mcarthur, H. L.; Hudis, C. A. |
| Article Title: | Has first-line therapy had an impact on general outcome in metastatic breast cancer? |
| Abstract: | According to the WHO World Cancer Report, 2003. breast cancer is a global public health burden with more than one million new cases diagnosed worldwide each year. Despite the diminished frequency of advanced-stage disease at initial diagnosis in some parts or the world, a significant proportion of women with early-stage disease eventually experience distant recurrences. Metastatic breast cancer is generally incurable and treatment is aimed of extending survival and improving quality-of-life. Efforts to optimize these paradigms are ongoing. In the last 30 years, significant innovations in drug delivery, scheduling and biologic therapies have resulted in significant improvements in disease-specific outcomet in the metastatic setting. One hopes that ongoing innovations, particularly in targeted therapy, will continue to translate into further improvements in this population. © 2007 Future Medicine Ltd. |
| Keywords: | cancer chemotherapy; cancer survival; treatment outcome; clinical trial; drug tolerability; neutropenia; bevacizumab; cytotoxic agent; doxorubicin; drug potentiation; monotherapy; risk benefit analysis; side effect; treatment duration; antineoplastic agents; capecitabine; gemcitabine; paclitaxel; adjuvant therapy; chemotherapy; cancer staging; neurotoxicity; outcome assessment; recurrent cancer; evidence based medicine; quality of life; breast cancer; antineoplastic combined chemotherapy protocols; ovariectomy; epidermal growth factor receptor 2; aromatase inhibitor; drug dosage form comparison; randomized controlled trials as topic; combination chemotherapy; antineoplastic activity; breast neoplasms; docetaxel; protein tyrosine kinase inhibitor; drug hypersensitivity; febrile neutropenia; antibodies, monoclonal; dosage schedule comparison; thromboembolism; neoplasm metastasis; tamoxifen; metastasis potential; bicalutamide; taxane derivative; premenopause; anthracycline derivative; biological therapy; trastuzumab; anastrozole; navelbine; postmenopause; lapatinib; drug delivery system; metastatic; ixabepilone; public health problem; epothilone derivative |
| Journal Title: | Future Oncology |
| Volume: | 3 |
| Issue: | 4 |
| ISSN: | 1479-6694 |
| Publisher: | Future Medicine |
| Date Published: | 2007-08-01 |
| Start Page: | 411 |
| End Page: | 418 |
| Language: | English |
| DOI: | 10.2217/14796694.3.4.411 |
| PUBMED: | 17661716 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 1" - "Export Date: 17 November 2011" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work